Showing 4591-4600 of 6036 results for "".
- Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and Wet AMD for 12- and 16-Week Dosinghttps://modernod.com/news/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wet-amd-for-12-and-16-week-dosing/2481071/Regeneron Pharmaceuticals announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The PHOTON trial in DME and the PUL
- TearLab Announces Corporate Name Change to Trukera Medical; Targets Corneal Healthhttps://modernod.com/news/tearlab-announces-corporate-name-change-to-trukera-medical-targets-corneal-health/2481067/TearLab announced that it will be expanding its position in corneal health under the new name Trukera Medical. The rebranding reflects the company’s vision and future growth strategy targeting a broader set of unmet needs across corneal health. “We continue to rema
- First US Patient Receives Autologous Stem Cell Therapy to Treat Dry AMDhttps://modernod.com/news/first-us-patient-receives-autologous-stem-cell-therapy-to-treat-dry-amd/2481061/At the National Institutes of Health, a surgical team successfully implanted a patch of tissue made from patient cells with the goal of treating advanced dry age-related macular degeneration (AMD), also known as geographic atrophy. The patient received the therapy as part of
- Vyluma Completes Last Patient Visit for Phase 3 CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-completes-last-patient-visit-for-primary-analysis-of-pivotol-phase-iii-champ-study-evaluating-nvk002-for-the-treatment-of-myopia-progression-in-children/2481059/Vyluma announced that the last patient visit has been completed for the primary analysis of the pivotal phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with the FDA, to evaluate whether NVK002 eye drops are safe and eff
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic
- Bausch + Lomb Announces Strategic Partnership With Munich Surgical Imaging GmbHhttps://modernod.com/news/bausch-lomb-announces-strategic-partnership-with-munich-surgical-imaging-gmbh-1/2481053/Bausch + Lomb announced its strategic partnership with Munich Surgical Imaging GmbH (MSI)—a wholly‐owned subsidiary of Heidelberg Engineering GmbH. Based in Munich, Germany, MSI develops state‐of‐the art digital visualization and image‐guided surgical applications. The new MSI platform, dev
- Outlook Therapeutics Resubmits Biologics License Application to FDA for Wet AMD Drug Candidate ONS-5010https://modernod.com/news/outlook-therapeutics-re-submits-biologics-license-application-for-ons-5010-as-a-treatment-for-wet-amd-to-the-fda/2481052/Outlook Therapeutics announced it has resubmitted its biologics license application (BLA) to the FDA for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD
- Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-24-month-results-showing-increased-effects-over-time-with-pegcetacoplan-in-phase-3-derby-and-oaks-studies-in-geographic-atrophy-ga/2481045/Apellis Pharmaceuticals announced topline data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Glaukos Licenses Iveena’s Investigational Keratoconus Therapyhttps://modernod.com/news/glaukos-licenses-iveenas-investigational-keratoconus-therapy/2481044/Glaukos has acquired an exclusive global license to develop and commercialize iVeena Delivery Systems' investigational pharmacologic treatment for keratoconus, IVMED-80. As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with development
- Oculis Announces Publication of Phase 2 Data Showing Eye Drop Drug Candidate Relieves Persistent Ocular Discomfort in Severe Dry Eye Diseasehttps://modernod.com/news/oculis-announces-publication-of-phase-2-data-showing-topical-eye-drop-drug-candidate-ocs-02-relieves-persistent-ocular-discomfort-in-severe-dry-eye-disease/2481042/Oculis announced that the results of the double blinded, multicenter and placebo controlled phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe dry eye disease (DED) has been published by the journal C